124 related articles for article (PubMed ID: 35289372)
1. Effectiveness of tacrolimus concomitant with biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
Terabe K; Takahashi N; Asai S; Hirano Y; Kanayama Y; Yabe Y; Oguchi T; Fujibayashi T; Ishikawa H; Hanabayashi M; Hattori Y; Suzuki M; Kishimoto K; Ohashi Y; Imaizumi T; Imagama S; Kojima T
Mod Rheumatol; 2023 Mar; 33(2):292-301. PubMed ID: 35289372
[TBL] [Abstract][Full Text] [Related]
2. Concomitant methotrexate and tacrolimus augment the clinical response to abatacept in patients with rheumatoid arthritis with a prior history of biological DMARD use.
Takahashi N; Fujibayashi T; Kida D; Hirano Y; Kato T; Kato D; Saito K; Kaneko A; Yabe Y; Takagi H; Oguchi T; Miyake H; Watanabe T; Hayashi M; Kanayama Y; Funahashi K; Hanabayashi M; Hirabara S; Asai S; Takemoto T; Terabe K; Asai N; Yoshioka Y; Ishiguro N; Kojima T
Rheumatol Int; 2015 Oct; 35(10):1707-16. PubMed ID: 25991396
[TBL] [Abstract][Full Text] [Related]
3. Comparison of efficacy and safety of tacrolimus and methotrexate in combination with abatacept in patients with rheumatoid arthritis; a retrospective observational study in the TBC Registry.
Fujibayashi T; Takahashi N; Kida D; Kaneko A; Hirano Y; Fukaya N; Yabe Y; Oguchi T; Tsuboi S; Miyake H; Takemoto T; Kawasaki M; Ishiguro N; Kojima T
Mod Rheumatol; 2015; 25(6):825-30. PubMed ID: 25775147
[TBL] [Abstract][Full Text] [Related]
4. Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study.
Ebina K; Hashimoto M; Yamamoto W; Hirano T; Hara R; Katayama M; Onishi A; Nagai K; Son Y; Amuro H; Yamamoto K; Maeda Y; Murata K; Jinno S; Takeuchi T; Hirao M; Kumanogoh A; Yoshikawa H
Arthritis Res Ther; 2019 Apr; 21(1):91. PubMed ID: 30971306
[TBL] [Abstract][Full Text] [Related]
5. Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study.
Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Takeuchi T; Shiba H; Son Y; Amuro H; Onishi A; Akashi K; Hara R; Katayama M; Yamamoto K; Kumanogoh A; Hirao M
Arthritis Res Ther; 2020 Jun; 22(1):142. PubMed ID: 32539813
[TBL] [Abstract][Full Text] [Related]
6. Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study.
Ebina K; Hashimoto M; Yamamoto W; Hirano T; Hara R; Katayama M; Onishi A; Nagai K; Son Y; Amuro H; Yamamoto K; Maeda Y; Murata K; Jinno S; Takeuchi T; Hirao M; Kumanogoh A; Yoshikawa H
PLoS One; 2019; 14(5):e0216624. PubMed ID: 31067271
[TBL] [Abstract][Full Text] [Related]
7. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
8. Safety and effectiveness of 6 months' etanercept monotherapy and combination therapy in Japanese patients with rheumatoid arthritis: effect of concomitant disease-modifying antirheumatic drugs.
Koike T; Harigai M; Inokuma S; Ishiguro N; Ryu J; Takeuchi T; Tanaka Y; Yamanaka H; Hirose T; Yoshinaga T; Suzukawa M
J Rheumatol; 2013 Oct; 40(10):1658-68. PubMed ID: 23908446
[TBL] [Abstract][Full Text] [Related]
9. Etanercept is effective as monotherapy or in combination with methotrexate in rheumatoid arthritis: subanalysis of an observational study.
Gaubitz M; Göttl KH; Behmer O; Lippe R; Meng T; Löschmann PA
Clin Rheumatol; 2017 Sep; 36(9):1989-1996. PubMed ID: 28756532
[TBL] [Abstract][Full Text] [Related]
10. Sustained Long-Term Retention Rates of Abatacept in Combination with Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis.
Sato S; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Yashiro-Furuya M; Asano T; Suzuki E; Watanabe H; Kanno T; Migita K
Medicina (Kaunas); 2021 Aug; 57(9):. PubMed ID: 34577837
[No Abstract] [Full Text] [Related]
11. Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study.
Ebina K; Hashimoto M; Yamamoto W; Ohnishi A; Kabata D; Hirano T; Hara R; Katayama M; Yoshida S; Nagai K; Son Y; Amuro H; Akashi K; Fujimura T; Hirao M; Yamamoto K; Shintani A; Kumanogoh A; Yoshikawa H
PLoS One; 2018; 13(3):e0194130. PubMed ID: 29543846
[TBL] [Abstract][Full Text] [Related]
12. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region.
Machado DA; Guzman RM; Xavier RM; Simon JA; Mele L; Pedersen R; Ferdousi T; Koenig AS; Kotak S; Vlahos B
J Clin Rheumatol; 2014 Jan; 20(1):25-33. PubMed ID: 24356474
[TBL] [Abstract][Full Text] [Related]
13. Comparing the effectiveness and safety of Abatacept and Tocilizumab in elderly patients with rheumatoid arthritis.
Temmoku J; Miyata M; Suzuki E; Sumichika Y; Saito K; Yoshida S; Matsumoto H; Fujita Y; Matsuoka N; Asano T; Sato S; Watanabe H; Migita K
PLoS One; 2022; 17(9):e0274775. PubMed ID: 36121851
[TBL] [Abstract][Full Text] [Related]
14. Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study.
Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Takeuchi T; Nagai K; Son Y; Amuro H; Onishi A; Jinno S; Hara R; Katayama M; Yamamoto K; Kumanogoh A; Hirao M
Clin Rheumatol; 2020 Sep; 39(9):2563-2572. PubMed ID: 32162152
[TBL] [Abstract][Full Text] [Related]
15. Longterm retention rate and risk factor for discontinuation due to insufficient efficacy and adverse events in Japanese patients with rheumatoid arthritis receiving etanercept therapy.
Matsubara H; Kojima T; Kaneko A; Hirano Y; Ishikawa H; Hattori Y; Miyake H; Oguchi T; Takagi H; Yabe Y; Kato T; Ito T; Fukaya N; Kanayama Y; Shioura T; Hayashi M; Fujibayashi T; Takahashi N; Funahashi K; Kato D; Hanabayashi M; Terabe K; Ishiguro N
J Rheumatol; 2014 Aug; 41(8):1583-9. PubMed ID: 25028370
[TBL] [Abstract][Full Text] [Related]
16. Long-term treatment response in rheumatoid arthritis patients starting adalimumab or etanercept with or without concomitant methotrexate.
l'Ami MJ; Kneepkens EL; Nurmohamed MT; Krieckaert CLM; Visman IM; Wolbink GJ
Clin Exp Rheumatol; 2017; 35(3):431-437. PubMed ID: 28079512
[TBL] [Abstract][Full Text] [Related]
17. Reasons and risk factors for discontinuation of treatment with any biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: A long-term observational study.
Terabe K; Takahashi N; Asai S; Hirano Y; Kanayama Y; Yabe Y; Oguchi T; Fujibayashi T; Ishikawa H; Hanabayashi M; Hattori Y; Suzuki M; Kishimoto K; Ohashi Y; Imaizumi T; Imagama S; Kojima T
Mod Rheumatol; 2023 Aug; 33(5):891-898. PubMed ID: 35975317
[TBL] [Abstract][Full Text] [Related]
18. Etanercept in combination with conventional disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis patients intolerant to methotrexate.
Koyama Y; Shiraishi H; Ohta T; Uchino A
Mod Rheumatol; 2012 Feb; 22(1):100-8. PubMed ID: 21706263
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
[TBL] [Abstract][Full Text] [Related]
20. Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort.
Shimizu Y; Tanaka E; Inoue E; Shidara K; Sugimoto N; Seto Y; Nakajima A; Momohara S; Taniguchi A; Yamanaka H
Mod Rheumatol; 2018 May; 28(3):461-467. PubMed ID: 28880684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]